SlideShare a Scribd company logo
Coronary Heart Disease Genetics: An Overview Amy Sturm, MS, CGC Certified Genetic Counselor Clinical Assistant Professor Division of Human Genetics Amy Sturm discloses significant financial interests or other relationships with commercial interests in the following areas: Consultant/Speaker Bureau:  Berkeley HeartLab. Presentation  will not  include discussion of commercial products or services and  will not  include unapproved or off-label usage of a commercial product or device. The following planning committee members have  no  significant financial interests or relationships with commercial interests to disclose, their educational unit  does not  have a financial interest or affiliation with an organization that may receive direct benefit from the subject of the proposed CME activity, and they  will not  be personally compensated for their role in the planning or execution of this proposed CME activity by an organization other than The Ohio State University:  Amy Ehrlich, MA  and Henry Zheng, PhD, MBA
Some Facts about CHD  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Heart Disease and Stroke Statistics — 2009 Update, American Heart Association
Established CHD Risk Factors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Monogenic versus Polygenic Disease ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Mendelian Disorders Featuring  CHD and/or MI ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Online Mendelian Inheritance in Man
Familial Dyslipidemias ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Crouch MA and Gramling R, Prim Care Clin Office Pract 2005
In Most Cases CHD is a Complex, Multifactorial Disease ,[object Object],[object Object],[object Object]
Most CHD-Associated Gene  Variants Have Low Penetrance ,[object Object],[object Object]
9p21 Example ,[object Object],[object Object],[object Object],[object Object],[object Object]
Familial Hypercholesterolemia (FH) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Family History of  Coronary Heart Disease ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Odds Ratios for Various Definitions of a “Positive Family History of CHD” ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Scheuner MT et al, Genet Med 2006
Familial Risk Stratification MI d. 85 MI d. 85 CAD dx. 67 MI dx. 53 MI d. 85 Diabetes dx. 45 Weak Risk  Moderate Risk  Strong Risk Published Risk Stratification Guidelines in Scheuner MT. Genet Med  2003 CAD dx. 67
Risk for Early-Onset CHD Given Familial  CHD Risk and Number of CVD Risk Factors CVD risk factors = diabetes, hypercholesterolemia, hypertension and obesity  Adjusted for age, gender, ethnicity/race, educational level, income, and marital status. Adapted from Table 4, Scheuner MT et al. Genet Med 2006 Familial CHD Risk Three or more n=376 OR a  (95% CI) Two n=740 OR a  (95% CI) One n=1203 OR a  (95% CI) None n=1716 OR a  (95% CI) Strong (n=1273) 62.2 (18.5-209.1) 48.6 (14.8-160.0) 17.9 (5.3-61.0) 4.3 (1.1-17.6) Moderate (n=471) 24.9 (5.2-119.7) 27.8 (7.2-106.8) 2.1 (0.21-20.0) 3.6 (0.6-21.9) Weak (n=2291) 16.5 (4.4-61.2) 12.6 (3.6-44.4) 3.7 (1.0-13.9) 1.0 (referent)
Genetic Susceptibility to CHD Be on the Watch for… ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Genetic Counseling for CHD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
What about Genetic Testing for CHD? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Case Example: Is This Woman at Increased Risk? d. 47 Heart Attack P Breast ca dx 35 40 35 61 d. 6 mo SIDS 10
Expanding the Pedigree… d. 47 Heart Attack P Breast ca dx 35 40 35 61 d. 6 mo SIDS 10 65 CABGx3, 62 Non-smoker 67 DM dx 55 HTN dx 45 d. 61 Heart attack Now what???
Familial Risk for Patient:  Strong d. 47 Heart Attack P Breast ca dx 35 40 35 61 d. 6 mo SIDS 10 65 CABGx3, 62 Non-smoker 67 DM dx 55 HTN dx 45 d. 61 Heart attack
CardioGenetic Consultation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Long-term Proband and  Family Follow-up P Breast ca dx 35 40 35 10 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Family History as a Guide for Early Detection and Prevention Modified from Scheuner MT. Genet Med 2003 Collect family history every 1-2 years High Moderate Average Possible Mendelian disorder? Assessment of established and emerging CHD risk factors every 1-2 yrs Consider early detection strategies every 2-3 yrs beginning 10 yrs before earliest CHD onset in family Provide personalized prevention strategies tailored to CHD risk factors and presence of subclinical disease Identify at-risk relatives Assessment of established CHD risk factors every 2-3 yrs If multiple risk factors identified, assign high risk Provide personalized prevention strategies tailored to CHD risk factors  Assessment of established CHD risk factors every 5 yrs Provide public health prevention messages
Useful Online Programs  to Estimate CHD Risk ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

More Related Content

What's hot

Familial hypercholestrolemia
Familial hypercholestrolemiaFamilial hypercholestrolemia
Familial hypercholestrolemia
promotemedical
 
RNA Interference (RNAi)
RNA Interference (RNAi)RNA Interference (RNAi)
RNA Interference (RNAi)
Suresh Antre
 
Identification of disease genes
Identification of disease genesIdentification of disease genes
Identification of disease genes
Prasanthperceptron
 
Genomic imprinting
Genomic imprintingGenomic imprinting
Genomic imprinting
mohamedkamal469
 
Niemann Pick Disease - Rivin
Niemann Pick Disease - RivinNiemann Pick Disease - Rivin
Niemann Pick Disease - Rivin
Rivindu Wickramanayake
 
Fragile x syndrome
Fragile x syndromeFragile x syndrome
Fragile x syndrome
Dr Prajith
 
Samuli Ripatti: Polygenic Risk and the GeneRisk Study
Samuli Ripatti: Polygenic Risk and the GeneRisk StudySamuli Ripatti: Polygenic Risk and the GeneRisk Study
Samuli Ripatti: Polygenic Risk and the GeneRisk Study
THL
 
Diagnosis of genetic diseases
Diagnosis of genetic diseasesDiagnosis of genetic diseases
Diagnosis of genetic diseases
Khalid Yousuf
 
Crispr cas: A new tool of genome editing
Crispr cas: A new tool of genome editing Crispr cas: A new tool of genome editing
Crispr cas: A new tool of genome editing
palaabhay
 
CRISPR
CRISPRCRISPR
CRISPR
Akash Arora
 
Exome seuencing (steps, method, and applications)
Exome seuencing (steps, method, and applications)Exome seuencing (steps, method, and applications)
Exome seuencing (steps, method, and applications)
Hamza Khan
 
What is Epigenetics?
What is Epigenetics?What is Epigenetics?
What is Epigenetics?
Garry D. Lasaga
 
Comparative Genomic Hybridization
Comparative Genomic HybridizationComparative Genomic Hybridization
Comparative Genomic HybridizationAhmed Ghobashi
 
Site specific recombination
Site specific recombination Site specific recombination
Site specific recombination
Ragavendran Abbai
 
Recombinase cre lox and flp-frt
Recombinase cre lox and flp-frtRecombinase cre lox and flp-frt
Recombinase cre lox and flp-frt
KAUSHAL SAHU
 
Derivatives of pBR322
Derivatives of pBR322Derivatives of pBR322
Derivatives of pBR322
ANKUR SHARMA
 

What's hot (20)

Familial hypercholestrolemia
Familial hypercholestrolemiaFamilial hypercholestrolemia
Familial hypercholestrolemia
 
RNA Interference (RNAi)
RNA Interference (RNAi)RNA Interference (RNAi)
RNA Interference (RNAi)
 
Identification of disease genes
Identification of disease genesIdentification of disease genes
Identification of disease genes
 
ChIP-seq Theory
ChIP-seq TheoryChIP-seq Theory
ChIP-seq Theory
 
Genomic imprinting
Genomic imprintingGenomic imprinting
Genomic imprinting
 
Niemann Pick Disease - Rivin
Niemann Pick Disease - RivinNiemann Pick Disease - Rivin
Niemann Pick Disease - Rivin
 
Epigenomics
EpigenomicsEpigenomics
Epigenomics
 
Fragile x syndrome
Fragile x syndromeFragile x syndrome
Fragile x syndrome
 
Samuli Ripatti: Polygenic Risk and the GeneRisk Study
Samuli Ripatti: Polygenic Risk and the GeneRisk StudySamuli Ripatti: Polygenic Risk and the GeneRisk Study
Samuli Ripatti: Polygenic Risk and the GeneRisk Study
 
Diagnosis of genetic diseases
Diagnosis of genetic diseasesDiagnosis of genetic diseases
Diagnosis of genetic diseases
 
Crispr cas: A new tool of genome editing
Crispr cas: A new tool of genome editing Crispr cas: A new tool of genome editing
Crispr cas: A new tool of genome editing
 
CRISPR
CRISPRCRISPR
CRISPR
 
Exome seuencing (steps, method, and applications)
Exome seuencing (steps, method, and applications)Exome seuencing (steps, method, and applications)
Exome seuencing (steps, method, and applications)
 
What is Epigenetics?
What is Epigenetics?What is Epigenetics?
What is Epigenetics?
 
Gene imprinting(edited)
Gene imprinting(edited)Gene imprinting(edited)
Gene imprinting(edited)
 
Comparative Genomic Hybridization
Comparative Genomic HybridizationComparative Genomic Hybridization
Comparative Genomic Hybridization
 
Type 2 Diabetes and Genes
Type 2 Diabetes and GenesType 2 Diabetes and Genes
Type 2 Diabetes and Genes
 
Site specific recombination
Site specific recombination Site specific recombination
Site specific recombination
 
Recombinase cre lox and flp-frt
Recombinase cre lox and flp-frtRecombinase cre lox and flp-frt
Recombinase cre lox and flp-frt
 
Derivatives of pBR322
Derivatives of pBR322Derivatives of pBR322
Derivatives of pBR322
 

Similar to Coronary Heart Disease

Genetics of Congenital Heart Disease
Genetics of Congenital Heart DiseaseGenetics of Congenital Heart Disease
Genetics of Congenital Heart Disease
Laxmi Ghimire
 
Heirlooms, Hope Chests and Genes...What did you inherit?
Heirlooms, Hope Chests and Genes...What did you inherit?Heirlooms, Hope Chests and Genes...What did you inherit?
Heirlooms, Hope Chests and Genes...What did you inherit?
Wisconsin Women's Health Foundation
 
Homocysteine
Homocysteine Homocysteine
Homocysteine
Hussam Elmouzi
 
Dyslipidemia in stroke
Dyslipidemia in stroke  Dyslipidemia in stroke
Dyslipidemia in stroke
NeurologyKota
 
Familial arterisclerosis
Familial arterisclerosisFamilial arterisclerosis
Familial arterisclerosis
Tapish Sahu
 
womenheartdisease.pptx
womenheartdisease.pptxwomenheartdisease.pptx
womenheartdisease.pptx
Niraj Raghani
 
190924 ICDA Kathiresan Genetics of Heart Attck
190924 ICDA Kathiresan Genetics of Heart Attck190924 ICDA Kathiresan Genetics of Heart Attck
190924 ICDA Kathiresan Genetics of Heart Attck
SekarKathiresan
 
Cardiac risk evaluation: searching for the vulnerable patient
Cardiac risk evaluation: searching for the vulnerable patient Cardiac risk evaluation: searching for the vulnerable patient
Cardiac risk evaluation: searching for the vulnerable patient
FELIX NUNURA
 
Chapter _05.ppt
Chapter                             _05.pptChapter                             _05.ppt
Chapter _05.ppt
AnthonyMatu1
 
Cap nhat lipid 2017
Cap nhat lipid 2017Cap nhat lipid 2017
Cap nhat lipid 2017
khacleson
 
Women heart (2)
Women heart (2)Women heart (2)
Women heart (2)
kiyyakoo
 
Congenital structural heart defects.
Congenital structural heart defects.Congenital structural heart defects.
Congenital structural heart defects.
Mohemet Khati
 
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
LupusNY
 
Cardiac Arrhythmias and Screening in Athletes
Cardiac Arrhythmias and Screening in AthletesCardiac Arrhythmias and Screening in Athletes
Cardiac Arrhythmias and Screening in Athletes
bwmf
 
Genetic basis for congenital heart defects
Genetic basis for congenital heart defectsGenetic basis for congenital heart defects
Genetic basis for congenital heart defectsgisa_legal
 
Heart Disease Analysis System
Heart Disease Analysis SystemHeart Disease Analysis System
Heart Disease Analysis System
ijtsrd
 
Are All FH patients the same ? Cardiovascular Risk Assessment in Familial Hyp...
Are All FH patients the same ? Cardiovascular Risk Assessment in Familial Hyp...Are All FH patients the same ? Cardiovascular Risk Assessment in Familial Hyp...
Are All FH patients the same ? Cardiovascular Risk Assessment in Familial Hyp...
James Underberg
 
heart and DNA.pptx
heart and DNA.pptxheart and DNA.pptx
heart and DNA.pptx
SaImoon QureShi
 
Jennifer Tremmel - Sex Differences In Cardiovascular Disease
Jennifer Tremmel - Sex Differences In Cardiovascular DiseaseJennifer Tremmel - Sex Differences In Cardiovascular Disease
Jennifer Tremmel - Sex Differences In Cardiovascular DiseaseClayman Institute
 
Inbreeding and congenital heart disease
Inbreeding and congenital heart diseaseInbreeding and congenital heart disease
Inbreeding and congenital heart disease
Ramachandra Barik
 

Similar to Coronary Heart Disease (20)

Genetics of Congenital Heart Disease
Genetics of Congenital Heart DiseaseGenetics of Congenital Heart Disease
Genetics of Congenital Heart Disease
 
Heirlooms, Hope Chests and Genes...What did you inherit?
Heirlooms, Hope Chests and Genes...What did you inherit?Heirlooms, Hope Chests and Genes...What did you inherit?
Heirlooms, Hope Chests and Genes...What did you inherit?
 
Homocysteine
Homocysteine Homocysteine
Homocysteine
 
Dyslipidemia in stroke
Dyslipidemia in stroke  Dyslipidemia in stroke
Dyslipidemia in stroke
 
Familial arterisclerosis
Familial arterisclerosisFamilial arterisclerosis
Familial arterisclerosis
 
womenheartdisease.pptx
womenheartdisease.pptxwomenheartdisease.pptx
womenheartdisease.pptx
 
190924 ICDA Kathiresan Genetics of Heart Attck
190924 ICDA Kathiresan Genetics of Heart Attck190924 ICDA Kathiresan Genetics of Heart Attck
190924 ICDA Kathiresan Genetics of Heart Attck
 
Cardiac risk evaluation: searching for the vulnerable patient
Cardiac risk evaluation: searching for the vulnerable patient Cardiac risk evaluation: searching for the vulnerable patient
Cardiac risk evaluation: searching for the vulnerable patient
 
Chapter _05.ppt
Chapter                             _05.pptChapter                             _05.ppt
Chapter _05.ppt
 
Cap nhat lipid 2017
Cap nhat lipid 2017Cap nhat lipid 2017
Cap nhat lipid 2017
 
Women heart (2)
Women heart (2)Women heart (2)
Women heart (2)
 
Congenital structural heart defects.
Congenital structural heart defects.Congenital structural heart defects.
Congenital structural heart defects.
 
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
 
Cardiac Arrhythmias and Screening in Athletes
Cardiac Arrhythmias and Screening in AthletesCardiac Arrhythmias and Screening in Athletes
Cardiac Arrhythmias and Screening in Athletes
 
Genetic basis for congenital heart defects
Genetic basis for congenital heart defectsGenetic basis for congenital heart defects
Genetic basis for congenital heart defects
 
Heart Disease Analysis System
Heart Disease Analysis SystemHeart Disease Analysis System
Heart Disease Analysis System
 
Are All FH patients the same ? Cardiovascular Risk Assessment in Familial Hyp...
Are All FH patients the same ? Cardiovascular Risk Assessment in Familial Hyp...Are All FH patients the same ? Cardiovascular Risk Assessment in Familial Hyp...
Are All FH patients the same ? Cardiovascular Risk Assessment in Familial Hyp...
 
heart and DNA.pptx
heart and DNA.pptxheart and DNA.pptx
heart and DNA.pptx
 
Jennifer Tremmel - Sex Differences In Cardiovascular Disease
Jennifer Tremmel - Sex Differences In Cardiovascular DiseaseJennifer Tremmel - Sex Differences In Cardiovascular Disease
Jennifer Tremmel - Sex Differences In Cardiovascular Disease
 
Inbreeding and congenital heart disease
Inbreeding and congenital heart diseaseInbreeding and congenital heart disease
Inbreeding and congenital heart disease
 

More from cphcosu

Genomics
GenomicsGenomics
Genomicscphcosu
 
Genetic Resources
Genetic ResourcesGenetic Resources
Genetic Resourcescphcosu
 
Diabetes
DiabetesDiabetes
Diabetescphcosu
 
Clotting Disorders
Clotting DisordersClotting Disorders
Clotting Disorderscphcosu
 
Breast Cancer
Breast CancerBreast Cancer
Breast Cancercphcosu
 
Alzhiemers
AlzhiemersAlzhiemers
Alzhiemerscphcosu
 

More from cphcosu (6)

Genomics
GenomicsGenomics
Genomics
 
Genetic Resources
Genetic ResourcesGenetic Resources
Genetic Resources
 
Diabetes
DiabetesDiabetes
Diabetes
 
Clotting Disorders
Clotting DisordersClotting Disorders
Clotting Disorders
 
Breast Cancer
Breast CancerBreast Cancer
Breast Cancer
 
Alzhiemers
AlzhiemersAlzhiemers
Alzhiemers
 

Recently uploaded

Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIONDACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
DR SETH JOTHAM
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 

Recently uploaded (20)

Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIONDACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 

Coronary Heart Disease

  • 1. Coronary Heart Disease Genetics: An Overview Amy Sturm, MS, CGC Certified Genetic Counselor Clinical Assistant Professor Division of Human Genetics Amy Sturm discloses significant financial interests or other relationships with commercial interests in the following areas: Consultant/Speaker Bureau: Berkeley HeartLab. Presentation will not include discussion of commercial products or services and will not include unapproved or off-label usage of a commercial product or device. The following planning committee members have no significant financial interests or relationships with commercial interests to disclose, their educational unit does not have a financial interest or affiliation with an organization that may receive direct benefit from the subject of the proposed CME activity, and they will not be personally compensated for their role in the planning or execution of this proposed CME activity by an organization other than The Ohio State University: Amy Ehrlich, MA and Henry Zheng, PhD, MBA
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13. Familial Risk Stratification MI d. 85 MI d. 85 CAD dx. 67 MI dx. 53 MI d. 85 Diabetes dx. 45 Weak Risk Moderate Risk Strong Risk Published Risk Stratification Guidelines in Scheuner MT. Genet Med 2003 CAD dx. 67
  • 14. Risk for Early-Onset CHD Given Familial CHD Risk and Number of CVD Risk Factors CVD risk factors = diabetes, hypercholesterolemia, hypertension and obesity Adjusted for age, gender, ethnicity/race, educational level, income, and marital status. Adapted from Table 4, Scheuner MT et al. Genet Med 2006 Familial CHD Risk Three or more n=376 OR a (95% CI) Two n=740 OR a (95% CI) One n=1203 OR a (95% CI) None n=1716 OR a (95% CI) Strong (n=1273) 62.2 (18.5-209.1) 48.6 (14.8-160.0) 17.9 (5.3-61.0) 4.3 (1.1-17.6) Moderate (n=471) 24.9 (5.2-119.7) 27.8 (7.2-106.8) 2.1 (0.21-20.0) 3.6 (0.6-21.9) Weak (n=2291) 16.5 (4.4-61.2) 12.6 (3.6-44.4) 3.7 (1.0-13.9) 1.0 (referent)
  • 15.
  • 16.
  • 17.
  • 18. Case Example: Is This Woman at Increased Risk? d. 47 Heart Attack P Breast ca dx 35 40 35 61 d. 6 mo SIDS 10
  • 19. Expanding the Pedigree… d. 47 Heart Attack P Breast ca dx 35 40 35 61 d. 6 mo SIDS 10 65 CABGx3, 62 Non-smoker 67 DM dx 55 HTN dx 45 d. 61 Heart attack Now what???
  • 20. Familial Risk for Patient: Strong d. 47 Heart Attack P Breast ca dx 35 40 35 61 d. 6 mo SIDS 10 65 CABGx3, 62 Non-smoker 67 DM dx 55 HTN dx 45 d. 61 Heart attack
  • 21.
  • 22.
  • 23. Family History as a Guide for Early Detection and Prevention Modified from Scheuner MT. Genet Med 2003 Collect family history every 1-2 years High Moderate Average Possible Mendelian disorder? Assessment of established and emerging CHD risk factors every 1-2 yrs Consider early detection strategies every 2-3 yrs beginning 10 yrs before earliest CHD onset in family Provide personalized prevention strategies tailored to CHD risk factors and presence of subclinical disease Identify at-risk relatives Assessment of established CHD risk factors every 2-3 yrs If multiple risk factors identified, assign high risk Provide personalized prevention strategies tailored to CHD risk factors Assessment of established CHD risk factors every 5 yrs Provide public health prevention messages
  • 24.

Editor's Notes

  1. Set C1 – Title Slide
  2. Why is font blue? Are the title fonts supposed to be calibri? Some slides have body font as calibri, some have it as Arial
  3. Set A1 – Content Slide
  4. While CHD is not caused by a single gene in most individuals, there are more than 30 single-gene, Mendelian disorders that feature CHD and/or MI. Tests for many of these disorders are available and include DNA-based tests and biochemical analyses. These conditions generally are associated with a substantial risk for coronary disease and heart attack at young ages, and should be included in the differential diagnosis for a family being seen with early onset CHD and MI.
  5. The familial dyslipidemias are an important subset of conditions that increase risk for premature CHD. Spacing between major bullets might help
  6. Gap between title and body is too less
  7. The color of title is different than on previous slides. Again, gap between title and body is too less
  8. Check title color. Check Bullet font size
  9. Same comment as prev slides
  10. Gap between title and body Body font size
  11. A recent study evaluated the impact on risk of additional family history beyond FDRs with early-onset CHD and found many additional significant associations, shown here as odds ratios, between additional family history characteristics and a personal history of early-onset CHD. This group used data from the national HealthStyles 2003 survey to assess associations between self-reported family history and personal history of early-onset CHD (diagnosed at or before age 60 years). These numbers are adjusted for demographic factors and self-reports of hypercholesterolemia, HTN, and obesity. 4035 respondents, 60% female, 72% white, mean age 48.8 years
  12. Also, stratification into average (or weak), moderate, and high (or strong)-risk groups is possible, taking into consideration the degree of relatedness of the affected relatives, the ages of diagnosis, and the number of affected relatives. For example, this is a weak risk family with just one 2 nd degree relative affected at a later age, a moderate risk family with two 2 nd degree relatives affected at later ages, and a strong risk family with one 1 st degree relative affected at an early age, as well as two 2 nd degree relatives affected at later ages.
  13. Also using data from the HealthStyles 2003 Survey, Scheuner et al. have published odds ratios for early-onset CHD given different combinations of level of familial risk, strong, moderate or weak and different numbers of CVD risk factors, which included diabetes, hypercholesterolemia, HTN, and obesity. Weak familial risk plus no other condition was the referent group. Early-onset CHD risk increased exponentially as the number of CVD risk factors and familial risk increased. Strong familial risk plus 3 or more risk factors was associated with a 62.2-fold increase in early-onset CHD risk compared with the referent group.
  14. In order to assess familial risk for CHD in the clinical setting, personal and family history characteristics of genetic susceptibility to CHD have been determined. These include [Read slide].
  15. Refer to a local cardiac genetic counselor or when that’s not possible, refer to a local preventative cardiologist. The components of a genetic evaluation for an individual referred because of concern due to a personal or family history of atherosclerosis include [Read slide].
  16. CHD develops as a result of the interplay between an individual’s environment and their genetic predisposition, therefore any genetic test to predict CHD must include such interactions in the algorithm.
  17. Set A1 – Content Slide
  18. Set A1 – Content Slide
  19. So, our proband has a strong familial risk for CHD.
  20. Set A1 – Content Slide
  21. Follow-up with our proband and her family showed that our proband [Read slide].
  22. Set A1 – Content Slide
  23. Regarding Michos study: They studied 102 asymptomatic women (mean age 51) who were the sisters of a proband hospitalized with documented premature CHD. 98% were at low risk according to FRE. Based on CAC score percentiles 32% had significant subclinical atherosclerosis and 17% ranked above the 90 th percentile. Sisters of probands with premature CHD appear to be a high-risk group and may warrant non-invasive screening for subclinical disease to appropriately target individuals for more aggressive primary preventive therapy. Other studies have had similar findings.